|
Match
|
Document |
Document Title |
|
|
9040057 |
Method of diagnosing and preventing pneumococcal diseases using pneumococcal neuraminidases
A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of... |
|
|
9040054 |
Hypoallergenic molecules
The present invention relates to a hypoallergenic molecule consisting of Bet v Ia or an allergen having at least 40% identity to Bet v Ia comprising mutations of at least four amino acid residues... |
|
|
9034339 |
Nucleic acid and amino acid sequences, and vaccine for the control of ectoparasite infestations in fish
The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a... |
|
|
9034337 |
Treatment and delay of outset of synucleinopathic and amyloidogenic disease
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such... |
|
|
9034338 |
Nucleic acid and amino acid sequences, and vaccine for the control of ectoparasite infestations in fish
The present invention is related with the isolation and cloning of a new gene, the production of the protein encoded by this gene by using recombinant systems, and the use of this antigen in a... |
|
|
9034341 |
Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
The invention relates to methods for controlling the glycosylation of a RAGE fusion protein. The invention also relates to compositions comprising an amount of a RAGE fusion protein where at least... |
|
|
9028816 |
Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
The present invention relates to polypeptides and polypeptide constructs comprising at least one single domain antibody directed against vWF, vWF A1 domain, A1 domain of activated vWF, vWF A3... |
|
|
9029502 |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
Provided herein are compounds that inhibit a binding interaction between an epidermal growth factor receptor (EGFR) and a heat shock protein 90 (HSP90), as well as compositions, e.g.,... |
|
|
9028842 |
Compositions and methods for treatment, research and therapeutic applications for malaria
The present invention provides anti-Plasmodium immunogenic compositions comprising EVP1 (PFD0495c) or an antigenic portion thereof, as well as methods of immunizing against malaria employing these... |
|
|
9023363 |
A1 moiety of cholera toxin A subunit as an adjuvant for mucosal and systemic vaccines
The present invention relates to cholera toxin CTA1 protein fragments, adjuvant compositions, and methods relating to adjuvants for vaccines. The invention also relates to using recombinant CTA1... |
|
|
9023364 |
Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus
Disclosed is a vaccine antigen capable of inducing a cross-reacting and neutralizing antibody directed against a high-risk-type human papillomavirus. Specifically disclosed are: a chimeric protein... |
|
|
9023367 |
Compositions comprising chimeric OSPA molecules and methods of use thereof
The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA... |
|
|
9023362 |
Immunological compositions as cancer therapeutics
The present invention concerns antibodies that react immunologically with an epitope comprising VDKSRWQQG (SEQ ID NO: 1), including those that bind to cancer cells, and methods relating thereto.... |
|
|
9023796 |
***WITHDRAWN PATENT AS PER THE LATEST USPTO WITHDRAWN LIST***
Antidotes for factor XA inhibitors and methods of using the same
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially... |
|
|
9017982 |
Non-wild-type organophosphorus acid anhydrolases for enzymatic decontamination
Provided are non-wild-type organophosphorus acid anhydrolases that are capable of degrading (ethyl {2-[bis(propan-2-yl)amino]ethyl}sulfanyl) (methyl)phosphinate and other V-agents. Particular... |
|
|
9017690 |
Epitopes related to coeliac disease
The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are... |
|
|
9018360 |
Modified biotin-binding protein
The present invention provides a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2 or its modified sequence and having a biotin-binding activity and... |
|
|
9012603 |
Peptides that block the binding of IgG to FcRn
The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods... |
|
|
9011867 |
Use of specific peptides in the preparation of a medicament for the treatment of monoclonal gammopathy of undetermined significance (MGUS) or of smoldering multiple myeloma (SMM)
The present invention relates to the use of a peptide comprising or essentially consisting of a sequence motif as shown in SEQ ID NO: 1 for the preparation of a medicament for the treatment of... |
|
|
9011871 |
Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease
The present invention is drawn to multivalent Salmonella enterica serovar conjugate vaccines comprising conjugates of S. Typhimurium, S. Enteritidis, S. Choleraesuis, S. Typhi, S. Paratyphi A and... |
|
|
9005627 |
Contiguous overlapping peptides for treatment of ragweed pollen allergy
Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of ragweed pollen Amb a 1. Such... |
|
|
9006404 |
Endometriosis cell targeting peptide and uses thereof
Provided herein are compositions and methods for selectively targeting an endometriosis cell. |
|
|
9005908 |
Mycobacterial infections
The present invention relates to Mycobacterial infections and provides a method of diagnosing infections of Mycobacterium avium subsp. paratuberculosis (Map), the causative agent of Johne's... |
|
|
RE45467 |
Streptococcus suis polypeptides and polynucleotides encoding same and their use in vaccinal and diagnostic applications
The present invention relates to the field of Streptococcus. More specifically, the present invention relates to the identification of polypeptides and polynucleotide sequences encoding the same... |
|
|
9005630 |
Fusion proteins for the treatment of allergic diseases
The present invention relates to a fusion protein comprising a first peptide and a second peptide linked together with a linker, wherein the first peptide is an allergen and the second peptide is... |
|
|
9005631 |
Membrane proximal region of HIV gp41 anchored to the lipid layer of a virus-like particle vaccine
Disclosed herein are isolated immunogens including variant hepatitis B surface antigens (HBsAgs). In an example, a variant HBsAg includes a HBsAg with one or more transmembrane domains of the... |
|
|
8999291 |
Compositions and methods for the removal of biofilms
This invention provides isolated or recombinant polypeptides that are useful to vaccinate individuals suffering from chronic/recurrent biofilm disease or as a therapeutic for those with an... |
|
|
8999349 |
HMGB1-derived peptides enhance immune response to antigens
The invention provides an immunostimulatory peptide containing the amino acid sequence SAFFLFCSE and uses thereof. The invention also provides an immunostimulatory peptide containing the amino... |
|
|
8999347 |
Vaccines for malaria
The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections,... |
|
|
8999348 |
Variants of group 6 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues
The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with... |
|
|
8999346 |
Immunogenic control of tumours and tumour cells
The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumour-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the... |
|
|
8999329 |
Agonist antibody to human thrombopoietin receptor
This invention provides an agonist antibody to a human thrombopoietin receptor (human c-Mpl), and pharmaceutical compositions comprising the same for use in treatment of thrombocytopenia. The... |
|
|
8993266 |
Proproteins activatable interferon alpha
The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which... |
|
|
8992942 |
Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M.... |
|
|
8993524 |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are... |
|
|
8986702 |
Antibodies and processes for preparing the same
Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments,... |
|
|
8986703 |
Peptide sequences and compositions
Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells... |
|
|
8986700 |
Immunogenic lipopeptides comprising T-helper and cytotoxic T-lymphocyte (CTL) epitopes
The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and CTL epitopes, and methods for their production and use in the generation of primary and... |
|
|
8980287 |
Anaplastic lymphoma kinase (ALK) as oncoantigen for lymphoma vaccination
Use of intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein and/or a nucleic acid molecule encoding for the intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein,... |
|
|
8981052 |
JNK inhibitor molecules
JNK inhibitor molecules are described. In addition, methods for raising antibodies against such JNK inhibitor molecules are disclosed. These antibodies and cells producing these antibodies are... |
|
|
8980574 |
Method for ameliorating radiation exposure effects with alpha-1 antitrypsin
Embodiments described herein relate to compositions, methods and uses for alpha-1 antitrypsin (AAT) or derivatives or analogs or peptides or mutants thereof for treating a subject exposed to... |
|
|
8974794 |
C(epsilon)mX peptides for inducing immune responses to human mIgE on B lymphocytes
The invention pertains to methods of using CεmX peptides (e.g., GLAGGSAQSQRAPDRVL; SEQ ID NO:2) that can bind effectively induce immune responses to membrane-bound IgE (mIgE) expressed on the... |
|
|
8974800 |
Proteins expressed by mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines
The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M.... |
|
|
8968745 |
Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid... |
|
|
8969524 |
FVIII peptides for immune tolerance induction and immunodiagnostics
The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore,... |
|
|
8961986 |
Peptide composition
There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also... |
|
|
8961981 |
Targeting the neuromuscular junction for treatment
Compositions and methods for targeting therapeutic agents to neuromuscular junctions are disclosed. Also disclosed are methods for treating diseases and conditions affecting the neuromuscular... |
|
|
8961984 |
Surface-coated structures and methods
The present invention relates to a method for covalently attaching a compound to a stainless steel, tin, iron, or titanium substrate, by contacting exposed surface(s) of the substrate with a... |
|
|
8961992 |
Epsigam fusion protein
Epsi-gam provides a novel fusion protein with the ability to cross-link either of the FcεRI or FcεRII cell surface receptors with an FcγRIIb cell surface receptor in order to block IgE-mediated... |
|
|
8962678 |
Senescence inhibitor
Provision of a drug, a quasi-drug, and a food or beverage, which are effective for senescence inhibition, mitochondrial function improvement, muscle dysfunction inhibition, muscular atrophy... |